Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Citius Pharmaceuticals (CTXR) stocks in Canada

Learn how to easily invest in Citius Pharmaceuticals stocks.

Citius Pharmaceuticals is a biotechnology business based in the US. Citius Pharmaceuticals stocks (CTXR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.16 – an increase of 0.4% over the previous week. Citius Pharmaceuticals employs 15 staff and has a market cap (total outstanding stock value) of $128.9 million.

How to buy stocks in Citius Pharmaceuticals

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTXR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Citius Pharmaceuticals stock price (NASDAQ:CTXR)

Use our graph to track the performance of CTXR stocks over time.

Citius Pharmaceuticals shares at a glance

Information last updated 2022-05-11.
Latest market close$0.90
52-week range$0.88 - $4.56
50-day moving average $1.46
200-day moving average $1.71
Wall St. target price$6.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.20

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Citius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Citius Pharmaceuticals price performance over time

Historical closes compared with the close of $0.9016 from 2022-05-18

1 week (2022-05-09) -4.26%
1 month (2022-04-19) -30.91%
3 months (2022-02-17) -49.63%
6 months (2021-11-15) N/A
1 year (2021-05-19) -58.83%
2 years (2020-05-19) 12.70%
3 years (2019-05-17) 1.38
5 years (2017-05-19) 124.28%

Citius Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -17.82%
Return on equity TTM -32.1%
Profit margin 0%
Book value $0.85
Market capitalisation $128.9 million

TTM: trailing 12 months

Citius Pharmaceuticals share dividends

We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.

Have Citius Pharmaceuticals's shares ever split?

Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.

Citius Pharmaceuticals share price volatility

Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.88 up to $4.56. A popular way to gauge a stock's volatility is its "beta".

CTXR.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.4113. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Citius Pharmaceuticals overview

Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site